Genetically modified immune cells take on deadly brain tumors

NCT ID NCT04991870

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests genetically engineered natural killer (NK) cells in 25 people with recurrent glioblastoma, an aggressive brain cancer. The cells are designed to resist the tumor's defenses. The main goal is to find a safe dose and check for side effects, while also watching for any signs of tumor control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT GLIOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma, IDH-mutant, grade 4 glioblastoma gliosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • M D Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact